HC Wainwright set a $25.00 price target on ObsEva (NASDAQ:OBSV) in a research report report published on Thursday morning. The brokerage currently has a buy rating on the stock.

Several other analysts also recently issued reports on the company. BMO Capital Markets began coverage on ObsEva in a research note on Monday, December 4th. They set an outperform rating and a $20.00 price target for the company. Royal Bank of Canada reiterated a buy rating and set a $22.00 price target on shares of ObsEva in a research note on Thursday, November 2nd. Zacks Investment Research upgraded ObsEva from a sell rating to a buy rating and set a $11.00 price target for the company in a research note on Wednesday, October 18th. Credit Suisse Group began coverage on ObsEva in a research note on Monday, October 9th. They set an outperform rating and a $16.00 target price for the company. Finally, Leerink Swann restated an outperform rating and set a $18.00 target price on shares of ObsEva in a research note on Wednesday, August 16th. Seven analysts have rated the stock with a buy rating, ObsEva has an average rating of Buy and a consensus target price of $19.00.

Shares of ObsEva (NASDAQ OBSV) traded up $0.03 during mid-day trading on Thursday, reaching $9.80. The company’s stock had a trading volume of 38,643 shares, compared to its average volume of 44,472. ObsEva has a 12 month low of $5.00 and a 12 month high of $14.69.

ObsEva (NASDAQ:OBSV) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.01). ObsEva’s quarterly revenue was up NaN% on a year-over-year basis. sell-side analysts anticipate that ObsEva will post -2.27 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its position in shares of ObsEva by 9.7% in the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after acquiring an additional 20,411 shares during the period. Abingworth LLP bought a new stake in shares of ObsEva in the 3rd quarter worth approximately $3,480,000. VHCP Management II LLC bought a new stake in shares of ObsEva in the 2nd quarter worth approximately $1,283,000. Sectoral Asset Management Inc lifted its position in shares of ObsEva by 181.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after acquiring an additional 137,331 shares during the period. Finally, Iguana Healthcare Management LLC lifted its position in shares of ObsEva by 66.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 35.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ObsEva (OBSV) Given a $25.00 Price Target at HC Wainwright” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/obseva-obsv-given-a-25-00-price-target-at-hc-wainwright/1766641.html.

ObsEva Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva (NASDAQ:OBSV)

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with Analyst Ratings Network's FREE daily email newsletter.